Icatibant 30 MG/3 ML syringe 3ML
Ended Awarded
- Contract number
- SPE2DB25FFJF9
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $44,464
Award facts
- Contract value 100% obligated
- $44,464.12 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency (DLA) awarded a delivery order valued at $44,464.12 to AmerisourceBergen Drug Corp for the supply of Icatibant 30 mg/3 mL syringes on September 15, 2025, with an ultimate completion date of September 16, 2025. This is a firm fixed-price, competitively awarded delivery order with no set-aside designation. The product will be delivered to the contractor's location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999.9 million through December 2026, which serves as a comprehensive global pharmaceutical support vehicle for military healthcare programs worldwide.
AmerisourceBergen Drug Corp is a major pharmaceutical distributor headquartered in Pennsylvania and serves as a critical vendor for federal medical procurement, particularly for Defense Health Agency and military healthcare systems. The company's substantial IDC enables it to supply a broad range of pharmaceutical products, specialty medications, generic drugs, vaccines, and medical supplies across multiple therapeutic domains to support military operations globally. This particular delivery order for Icatibant, a bradykinin B2 receptor antagonist used in emergency treatment of hereditary angioedema, exemplifies the company's role in providing specialized pharmaceutical commodities essential to military medical readiness.
Quick answers
Who was awarded contract SPE2DB25FFJF9?
SPE2DB25FFJF9 was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on September 15, 2025.
How much is contract SPE2DB25FFJF9 worth?
The government has obligated $44,464 on SPE2DB25FFJF9.
Is contract SPE2DB25FFJF9 an order under another contract?
Yes. SPE2DB25FFJF9 is a delivery order under SPE2DB22D1106, an indefinite delivery contract.
Was contract SPE2DB25FFJF9 competed?
The extent of competition for SPE2DB25FFJF9 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award